Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 332

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 332
---
,312,010 for the six months ended June 30, 2023. This decrease was mainly due to the reduction in general and administrative expenses and Kadimastem’s efficiency measures during the period ended June 30, 2024. Net cash used in operating activities for the year ended December 31, 2023, was $3,004,813 representing a decrease of $2,950,385 (49.5%), compared to $5,955,198 for the year ended December 31, 2022. This decrease was mainly due to the reduction in general and administrative expenses and Kadimastem’s efficiency measures during the reporting period which included a reduction in research and development expenses. Net Cash Used in Investing Activities Net cash used in investing activities for the six months ended June 30, 2024, was $112,399, reflecting a decrease of $25,976 (18.7%), compared to $138,375 for the six months ended June 30, 2023. The decrease was mainly attributed to changes in bank deposits during the six months ended June 30, 2023. Net cash received in investing activities for the year ended December 31, 2023, was $90,250, reflecting an increase of $105,120 (53.8%), compared to cash used of $195,370 for the year ended December 31, 2022. The change was mainly attributed to changes in bank deposits during the year ended December 31, 2023. Net Cash Provided by Financing Activities Over the period 2021 -2024, the company raised approximately USD $15.3million in equity for the issuance of 2,146,899shares. In the years 2021 to 2024, the company received grants from the Bird Foundation, the Israel Innovation Authority and the Australian Innovation Authority totaling USD $2.4million Net cash provided by financing activities for the six months ended June 30, 2024, amounted to $925,173, representing a decrease of $4,037,907, (81%), compared to $4,963,080 for the six months ended June 30, 2023. This decrease was primarily due to capital raised by Kadimastem during June 30, 2024 compared to the previous period. Net cash provided by financing activities for the year ended December 31, 2023, amounted to $2,328,073, representing an increase of $1,218,993